Vertex Wins FDA Approval for Expanded Cystic Fibrosis Treatment
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares saw a handy gain on Thursday after the U.S. Food and Drug Administration (FDA) gave the...


Cystic Fibrosis Treatment Approved for Use in Children Aged 2 to 5 Years
Officials with the FDA have updated the label of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals), approving the treatment's use in...


Vertex Pharma (VRTX) Receives European CHMP Positive Opinion for SYMKEVI for People with CF Aged 12
Vertex Pharmaceuticals (Europe) Limited (Nasdaq: VRTX), today announced that the European Medicines Agency’s (EMA) Committee for...


Vertex Anticipates Completing Enrollment of Phase 3 Trials Testing Triple Combo Therapies
Vertex Pharmaceuticals plans to conclude the enrollment of patients in its Phase 3 programs involving its triple combo therapies to treat...


Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement...


Nanoparticles Therapy May Be ‘One-Size-Fits-All’ Approach for CF, Study Suggests
A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic...


Vertex Pharmaceuticals opens expanded San Diego research center with focus on cystic fibrosis
Vertex Pharmaceuticals opened its new San Diego research center Monday, starting a new chapter in a decades-long quest to not only treat...


Vertex Announces VX-445 Phase 3 Trial Program, Positive Data on VX-561 Combo Regimen
Vertex Pharmaceuticals is launching Phase 3 clinical trials to evaluate the safety and effectiveness of its investigational therapy,...


Vertex’s VX-659 Triple Combo To Be Tested in Phase 3 Trial in Patients with 2 Copies of F508del Muta
Vertex Pharmaceuticals is launching a new Phase 3 trial to assess the triple combination of VX-659 plus tezacaftor (VX-661) and Kalydeco...


Cystic fibrosis drug Orkambi 'approved for use among 6-11 year olds'
The pharmaceutical firm making cystic fibrosis drug Orkambi says it has received EU approval to treat children. Manufacturer Vertex says...

